Get the Stockscreener App
0.8661
0.10%
-0.0009
After Hours:
.88
0.0139
+1.60%
Sangamo Therapeutics Inc stock is traded at $0.8661, with a volume of 1.51M.
It is down -0.10% in the last 24 hours and up +2.13% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.867
Open:
$0.8583
24h Volume:
1.51M
Relative Volume:
0.11
Market Cap:
$176.47M
Revenue:
$176.23M
Net Income/Loss:
$-257.83M
P/E Ratio:
-0.5973
EPS:
-1.45
Net Cash Flow:
$-246.00M
1W Performance:
-5.34%
1M Performance:
+2.13%
6M Performance:
+29.23%
1Y Performance:
+44.40%
1-Day Range:
$0.8408
$0.8961
1-Week Range:
$0.836
$0.959
52-Week Range:
$0.2911
$1.48
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com
Sangamo Therapeutics (NASDAQ:SGMO) Shares Cross Above 200-Day Moving Average of $0.64 - MarketBeat
Armistice Capital LLC Sells 2,898,477 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64 - Defense World
Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2022-2030 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews
Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance
Sangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO) - MarketBeat
Press Release Service: Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex PharmaceuticalsResearchAndMarkets.comC - CRISPR Medicine News
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs - MSN
Bay Area biotech company cutting 40% of workforce, closing Brisbane headquarters - MSN
Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2024- 2033 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
Hemoglobinopathies Market 2024 Trend Analysis and Top Manufacturers Operating as Gamida Cell, Alnylam Pharmaceuticals, Inc, Sangamo Therapeutics – Cauverynews - Cauverynews
Genome Editing Market Worth Observing Growth: Merck KGaA, Thermo Fisher Scientific, Lonza, Sangamo Therapeutics, GenScript – Cauverynews - Cauverynews
Sangamo Therapeutics (NASDAQ:SGMO) Shares Pass Above Two Hundred Day Moving Average of $0.66 - MarketBeat
10 Promising Biotech Stocks to Invest in (September 2024) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.
Short Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Decreases By 16.6% - Defense World
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
HC Wainwright Comments on Sangamo Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:SGMO) - MarketBeat
Q4 2025 EPS Estimates for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Cut by Analyst - Defense World
Q4 2025 EPS Estimates for Sangamo Therapeutics, Inc. Reduced by HC Wainwright (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Receives “Buy” Rating from HC Wainwright - Defense World
East Bay biotech company takes aim at one-in-a-million disease. First it needs millions more in cash - The Business Journals
East Bay biotech company takes aim at one-in-a-million disease. First it needs millions more in cash - San Francisco Business Times
Vanguard Group Inc. Sells 398,761 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short Interest - MarketBeat
Financial Respite For Sangamo As Roche Signs Neurodegeneration Disease Pact - Scrip
Sangamo Therapeutics (NASDAQ:SGMO) and TScan Therapeutics (NASDAQ:TCRX) Critical Survey - Defense World
Sangamo Therapeutics (SGMO-Q) QuotePress Release - The Globe and Mail
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Sangamo Therapeutics Second Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Sangamo Revenue Drops Due To Collaboration Endings - Contract Pharma
Earnings call: Sangamo Therapeutics extends cash runway into 2025 - Investing.com
Genentech-Sangamo deal to advance neurodegenerative treatments - Marketscreener.com
Genentech-Sangamo deal to advance neurodegenerative treatments - European Pharmaceutical Review
Sangamo soars as it links up with Genentech on neurodegenerative diseases - The Pharma Letter
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Call Transcript - Insider Monkey
Sangamo: Q2 Earnings Snapshot - San Antonio Express-News
Genentech and Sangamo to develop neurodegenerative disease therapies - Yahoo Finance
Genentech and Sangamo to develop new therapies - Pharmaceutical Technology
Roche inks US$2bn biobucks deal with Sangamo - European Biotechnology News
Roche strikes new deal with Sangamo to tackle Alzheimer's - Proactive Investors UK
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript - Seeking Alpha
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Stock Traders Buy Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO) - Defense World
Sangamo inks deal with Genentech for neurodegenerative treatments By Investing.com - Investing.com Australia
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):